InsidersTradesSigma
Total declarations
Company
▲ Purchases (12 ops.)
▼ Sales (0 ops.)
Browse the complete record of transactions filed by Lin Patrick, Directeur Stratégie. Insider active across 1 companies, notably Processa Pharmaceuticals, Inc.. Aggregated, 14 reports have been logged. Total volume traded: €142k. The latest transaction was filed on 17 May 2022 — Acquisition. Regulator: SEC (Form 4). All data is openly available.
Declarations14 total
€3,0232,000 shares@ €1.51170.046% mcap2.1% of flow
Common Stock
SEC:0001567619-22-011300:0·
Ideal exit: 11 Feb 2023 (T+270)
€3,4431,200 shares@ €2.8690.053% mcap2.4% of flow
Common Stock
SEC:0001567619-22-008312:0·
Ideal exit: 1 Jan 2023 (T+270)
€10,6333,000 shares@ €3.54440.16% mcap15.7% of flow
Common Stock
SEC:0001567619-22-000291·
Ideal exit: 10 Sept 2022 (T+270)
€10,6333,000 shares@ €3.54440.16% mcap7.5% of flow
Common Stock
SEC:0001567619-22-000291:0·
Ideal exit: 10 Sept 2022 (T+270)
€10,6333,000 shares@ €3.54440.16% mcap15.7% of flow
Common Stock
SEC:0001567619-21-022195·
Ideal exit: 10 Sept 2022 (T+270)
€10,6333,000 shares@ €3.54440.16% mcap7.5% of flow
Common Stock
SEC:0001567619-21-022195:0·
Ideal exit: 10 Sept 2022 (T+270)
€14,8553,500 shares@ €4.24420.23% mcap21.9% of flow
Common Stock
SEC:0001567619-21-021708·
Ideal exit: 30 Aug 2022 (T+270)
€14,8553,500 shares@ €4.24420.23% mcap10.5% of flow
Common Stock
SEC:0001567619-21-021708:0·
Ideal exit: 30 Aug 2022 (T+270)
€20,4894,000 shares@ €5.12230.31% mcap30.2% of flow
Common Stock
SEC:0001567619-21-016470·
Ideal exit: 23 May 2022 (T+270)
€20,4894,000 shares@ €5.12230.31% mcap14.4% of flow
Common Stock
SEC:0001567619-21-016470:0·
Ideal exit: 23 May 2022 (T+270)
7,601 shares
Common Stock
SEC:0001567619-21-014747·
7,601 shares
Common Stock
SEC:0001567619-21-014747:0·
€11,1652,000 shares@ €5.58230.17% mcap16.5% of flow
Common Stock
SEC:0001567619-21-012486·
Ideal exit: 18 Mar 2022 (T+270)
€11,1652,000 shares@ €5.58230.17% mcap7.9% of flow
Common Stock
SEC:0001567619-21-012486:0·
Ideal exit: 18 Mar 2022 (T+270)
14 of 14 declarations
About Lin Patrick
Patrick Lin is Chief Business - Strategy Officer at Processa Pharmaceuticals, Inc. He is responsible for defining and implementing the company's business strategies. His expertise in strategic development is essential for guiding the company towards sustainable and innovative growth.
